Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomar...

Full description

Bibliographic Details
Main Authors: Moritz Schnelle, Andreas Leha, Abass Eidizadeh, Katharina Fuhlrott, Tobias D. Trippel, Djawid Hashemi, Karl Toischer, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Burkert Pieske, Lutz Binder, Frank Edelmann
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cells
Subjects:
plasma biomarkers
heart failure with preserved ejection fraction
spironolactone
Online Access:https://www.mdpi.com/2073-4409/10/10/2796

Internet

https://www.mdpi.com/2073-4409/10/10/2796

Similar Items